New drug target for prostate cancer found in the non-coding genome
Thursday, January 23, 2020 - 05:31
in Health & Medicine
Scientists at Princess Margaret Cancer Centre have identified the drivers of a crucial gene involved in prostate cancer, revealing new targets for drug design. Researchers identified a set of cis-regulatory elements - namely enhancers and the promoter - in the non-coding region of the genome, which affect the expression of FOXA1 gene, one of the major drivers or oncogenes involved in prostate cancer development.